BioTech IP Review

Assignee: IGC Pharma, Inc.
Patent Number: 12,465,589
Filed: (Typical sequence begins earlier; patent granted Nov 11, 2025)
Issued: November 11, 2025
Title: Methods and Composition for Treating CNS Disorders

What This Patent Covers

This U.S. patent protects a proprietary pharmaceutical composition and associated methods used in IGC‑AD1, the company’s lead drug candidate currently in a Phase 2 clinical trial (CALMA) for agitation in Alzheimer’s disease.

Key elements include:

• A novel therapeutic formulation designed to address both behavioral symptoms (e.g., agitation, anxiety, sleep disturbances) and core pathological features of Alzheimer’s disease (such as amyloid plaque and tau tangles).
• Composition that reduces amyloid‑β expression/aggregation, enhances mitochondrial function, reduces tau phosphorylation, and impacts related neurobiological pathways — all aimed at modifying disease progression, not just symptomatic relief.
• Methods for using this formulation to treat central nervous system (CNS) disorders, particularly Alzheimer’s, by targeting multiple disease mechanisms and associated symptoms.

Why This Patent Is Important

• Core to Lead Asset: It protects the intellectual property for IGC‑AD1, the company’s most advanced candidate, which is central to its clinical and commercial strategy.
• Broader Therapeutic Scope: The claims extend beyond simple symptomatic treatment to include disease‑modifying mechanisms in Alzheimer’s, potentially differentiating IGC‑AD1 from many other therapeutics that only address symptoms.
• Commercial Leverage: Patent protection strengthens exclusivity ahead of future regulatory filings and helps support valuation, investor confidence, and potential partnerships or licensing deals.
• Foundation for Expansion: Protecting this formulation also underpins IGC’s broader portfolio strategy in CNS disorders and AI‑driven drug discovery for neurodegenerative diseases.